1. Home
  2. VINP vs CRGX Comparison

VINP vs CRGX Comparison

Compare VINP & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VINP
  • CRGX
  • Stock Information
  • Founded
  • VINP 2009
  • CRGX 2021
  • Country
  • VINP Brazil
  • CRGX United States
  • Employees
  • VINP N/A
  • CRGX N/A
  • Industry
  • VINP Investment Managers
  • CRGX
  • Sector
  • VINP Finance
  • CRGX
  • Exchange
  • VINP Nasdaq
  • CRGX Nasdaq
  • Market Cap
  • VINP 593.2M
  • CRGX 190.0M
  • IPO Year
  • VINP 2021
  • CRGX 2023
  • Fundamental
  • Price
  • VINP $9.66
  • CRGX $4.40
  • Analyst Decision
  • VINP Strong Buy
  • CRGX Hold
  • Analyst Count
  • VINP 2
  • CRGX 7
  • Target Price
  • VINP $13.25
  • CRGX $4.67
  • AVG Volume (30 Days)
  • VINP 51.9K
  • CRGX 527.8K
  • Earning Date
  • VINP 08-06-2025
  • CRGX 08-11-2025
  • Dividend Yield
  • VINP 6.67%
  • CRGX N/A
  • EPS Growth
  • VINP N/A
  • CRGX N/A
  • EPS
  • VINP 0.38
  • CRGX N/A
  • Revenue
  • VINP $126,696,258.00
  • CRGX N/A
  • Revenue This Year
  • VINP $70.28
  • CRGX $57.81
  • Revenue Next Year
  • VINP $14.37
  • CRGX N/A
  • P/E Ratio
  • VINP $25.61
  • CRGX N/A
  • Revenue Growth
  • VINP 57.51
  • CRGX N/A
  • 52 Week Low
  • VINP $8.66
  • CRGX $3.00
  • 52 Week High
  • VINP $11.62
  • CRGX $25.45
  • Technical
  • Relative Strength Index (RSI)
  • VINP 51.03
  • CRGX 55.41
  • Support Level
  • VINP $9.43
  • CRGX $4.09
  • Resistance Level
  • VINP $9.94
  • CRGX $4.31
  • Average True Range (ATR)
  • VINP 0.25
  • CRGX 0.19
  • MACD
  • VINP 0.02
  • CRGX -0.01
  • Stochastic Oscillator
  • VINP 55.71
  • CRGX 61.61

About VINP Vinci Partners Investments Ltd.

Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

Share on Social Networks: